{"id":4860,"date":"2020-07-19T18:50:30","date_gmt":"2020-07-19T16:50:30","guid":{"rendered":"https:\/\/studienportal-brustkrebs.de\/current-news-from-science-and-practice\/"},"modified":"2025-07-30T11:44:59","modified_gmt":"2025-07-30T09:44:59","slug":"current-news-from-science-and-practice","status":"publish","type":"page","link":"https:\/\/studienportal-brustkrebs.de\/en\/current-news-from-science-and-practice\/","title":{"rendered":"Current News from Science and Practice"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

News<\/strong>
Current News from Science and Practice<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n
\n

HERTHENA-Breast04<\/a><\/h3><\/header>
\n

HERTHENA-Breast04 THERAPEUTIC TRIAL EVALUATING PATRITUMAB DERUXTECAN IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER Die HERTHENA-Breast04-Studie ist eine internationale, randomisierte (die Zuordnung in die Behandlungsgruppe erfolgt nach dem Zufallsprinzip)...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

EXPRESSION XVIII (18)<\/a><\/h3><\/header>
\n

NOGGO S30 – EXPRESSION XVIII (18) INTERNATIONAL SURVEY ON THE IMPACT OF CRISES ON PATIENTS WITH GYNECOLOGICAL TUMORS Anxiety is a central issue in cancer patients with gynecologic diseases and...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

New study results on breast cancer<\/a><\/h3><\/header>
\n

New study results on breast cancer 1. Early breast cancer: If breast cancer is detected early (at a stage where the tumor is locally confined and has not yet spread),...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

EMRISK<\/a><\/h3><\/header>
\n

NOGGO S18 – EMRISK DEVELOPMENT OF A RISK PREDICTION MODEL FOR NAUSEA AND VOMITING DURING CHEMOTHERAPY What is being investigated in this study? The EMRISK study is a two-phase observational...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

The most important ASCO results on breast cancer<\/a><\/h3><\/header>
\n

The 26th NOGGO update on gynecologic oncology took place at the end of June, where important studies on breast cancer from ASCO 2025 were presented. We were there and would...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

EvoPAR-Breast01<\/a><\/h3><\/header>
\n

EvoPAR-Breast01 Study STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION THERAPY WITH SARUPARIB AND CAMIZESTRANT IN THE TREATMENT OF PATIENTS WITH HER2-NEGATIVE, ER-POSITIVE, ADVANCED BREAST CANCER Die EvoPAR-Breast01...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

CAPItello-292<\/a><\/h3><\/header>
\n

CAPItello-292 Study THERAPY STUDY TO EVALUATE A NEW COMBINATION THERAPY WITH CAPIVASERTIB, FULVESTRANT AND A CDK4\/6 INHIBITOR IN PATIENTS WITH HER2-NEGATIVE, HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER Die CAPItello-292 ist eine...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

New Approaches against Metastatic Breast Cancer: Mini-Tumors from Circulating Tumor Cells<\/a><\/h3><\/header>
\n

New Approaches against Metastatic Breast Cancer: Mini-Tumors from Circulating Tumor Cells On January 3, 2025, the German Cancer Research Center (DKFZ) published an exciting press release on the results of...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

CAMBRIA-2<\/a><\/h3><\/header>
\n

CAMBRIA-2 Study THERAPEUTIC STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT IN THE TREATMENT OF PATIENTS WITH ER-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER Die CAMBRIA-2 ist eine offene (behandelnde \u00c4rzt:innen...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

CAMBRIA-1<\/a><\/h3><\/header>
\n

CAMBRIA-1 Study THERAPY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT IN THE TREATMENT OF PATIENTS WITH ER-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER Die CAMBRIA-1 ist eine offene (behandelnde \u00c4rzt:innen...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

Breast Cancer Study Showed Improved Progression-Free Survival in Advanced HR+, HER2- Breast Cancer<\/a><\/h3><\/header>
\n

  Breast Cancer Study Showed Improved Progression-Free Survival in Advanced HR+, HER2- Breast Cancer A new Phase III breast cancer study, led by Dr. K\u00fcmmel, shows promising results for the...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

Epik-B5<\/a><\/h3><\/header>
\n

EPIK-B5 Study This study can enroll adult men and postmenopausal women with advanced HR-positive, HER2-negative breast cancer with a PIK3CA mutation Breast cancer has various classifications, including by stage or...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

EMBER-4<\/a><\/h3><\/header>
\n

EMBER-4 Study Endocrine therapy with Imlunestrant in high-risk patients with early ER-positive and HER2-negative breast cancer and completed endocrine therapy EMBER-4 is a randomized, unblinded (patients and physicians know the...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

Prof. K\u00fcmmel – Methadone for Cancer?<\/a><\/h3><\/header>
\n

Prof. K\u00fcmmel – Methadone for Cancer? You are currently viewing a placeholder content from Default. To access the actual content, click the button below. Please note that doing so will...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

Change from July 1 – Mammography Screening also for Women Aged 70-75<\/a><\/h3><\/header>
\n

Change from July 1 – Mammography Screening also for Women Aged 70-75 From July 1, 2024, the mammography screening program for early detection of breast cancer will...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

SURVIVE Breast Cancer Study with Prof. Janni<\/a><\/h3><\/header>
\n

Prof. Janni from Ulm University Hospital presented the SURVIVE study to us at the Post-ASCO, the 25th NOGGO Gynecological Oncology Update in Berlin. It summarized the most important and latest...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

Merck’s Phase 3 Study Shows Success in Breast Cancer Treatment<\/a><\/h3><\/header>
\n

Merck announced that the Phase 3 KEYNOTE-522 study of Keytruda (anti-PD-1 therapy) met its overall survival endpoint in high-risk early-stage triple-negative breast cancer (TNBC). In combination with chemotherapy as a...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

TROPION-Breast04 (Recruitment completed)<\/a><\/h3><\/header>
\n

TROPION-Breast04 Study Therapy with antibody-drug conjugate and immunotherapy or standard therapy in previously untreated patients with early-stage triple-negative breast cancer Recruitment for the TROPION-Breast04 study has already been completed. TROPION-Breast04...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

MINERVA Study<\/a><\/h3><\/header>
\n

MINERVA Study Combination therapy with Abemaciclib and endocrine therapy in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer with a focus on digital side effect management https:\/\/youtu.be\/MRxnbZA1Kn8...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

SURVIVE Study<\/a><\/h3><\/header>
\n

SURVIVE Study Breast cancer aftercare study for women and men with early-stage breast cancer, comparing standard aftercare with intensified aftercare https:\/\/www.youtube.com\/watch?v=5EhOeRa2CJo&ab_channel=ForumGynOnkologie What is being investigated in this study? The SURVIVE...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

ADAPTlate – Study<\/a><\/h3><\/header>
\n

ADAPTlate Study Personalized therapy study in patients with hormone receptor-positive, HER2 receptor-negative early-stage breast cancer who have a clinically or genomically high risk of late recurrence The ADAPTlate is a...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

PROVIDENCE Study<\/a><\/h3><\/header>
\n

PROVIDENCE Study A non-interventional study to collect clinical and quality of life data in patients with HER2+ or HER2-low inoperable or metastatic breast cancer who receive trastuzumab deruxtecan as second-line...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

GeparPiPPa \/ GBG-105<\/a><\/h3><\/header>
\n

GeparPiPPa \/ GBG-105 THERAPY STUDY TO EVALUATE THE POTENTIAL ADDITIONAL EFFICACY AND SAFETY OF INAVOLISIB IN THE PRE-OPERATIVE TREATMENT OF PATIENTS WITH HER2-POSITIVE, HR-POSITIVE, PIK3CA-MUTATED EARLY BREAST CANCER. GeparPiPPa is...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

New Approval for the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer<\/a><\/h3><\/header>
\n

New Approval for the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer Currently, the treatment of metastatic breast cancer that is hormone receptor-positive (HR+) and does not express human epidermal growth...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

PROOFS – Registry Study<\/a><\/h3><\/header>
\n

PROOFS – Registry Study A REGISTRY STUDY FOR LONG-TERM FOLLOW-UP OF PATIENTS WITH EARLY-STAGE LUMINAL BREAST CANCER WHO ARE TREATED WITH ENDOCRINE THERAPY PLUS OVARIAN FUNCTION SUPPRESSION (OFS) OR STANDARD...<\/p>Read More<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article><\/div>\n

<\/div>\n <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

NewsCurrent News from Science and Practice EvoPAR-Breast01 EvoPAR-Breast01-Studie STUDIE ZUR BEWERTUNG DER WIRKSAMKEIT UND SICHERHEIT EINER KOMBINATIONSTHERAPIE MIT SARUPARIB UND CAMIZESTRANT IN DER BEHANDLUNG VON PATIENT:INNEN MIT HER2-NEGATIVEM, ER-POSITIVEM, FORTGESCHRITTENEM BRUSTKREBS Die EvoPAR-Breast01 ist eine offene (Behandelnde… Read More CAPItello-292 CAPItello-292-Studie THERAPIESTUDIE ZUR BEWERTUNG EINER NEUEN KOMBINATIONSTHERAPIE MIT CAPIVASERTIB, FULVESTRANT UND EINEM CDK4\/6-HEMMER BEI PATIENT:INNEN […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-4860","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/pages\/4860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/comments?post=4860"}],"version-history":[{"count":1,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/pages\/4860\/revisions"}],"predecessor-version":[{"id":4862,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/pages\/4860\/revisions\/4862"}],"wp:attachment":[{"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/media?parent=4860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}